EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice

Charanya Muralidharan, Fei Huang, Jacob R Enriquez, Jiayi E Wang, Jennifer B Nelson, Titli Nargis, Sarah C May, Advaita Chakraborty, Kayla T Figatner, Svetlana Navitskaya, Cara M Anderson, Veronica Calvo und 13 weitere

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci176136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Charanya Muralidharan und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and the Kovler Diabetes Center, The University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: eIF-2 Kinase, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preventing the onset of autoimmune type 1 diabetes (T1D) is feasible through pharmacological interventions that target molecular stress–responsive mechanisms. Cellular stresses, such as nutrient deficiency, viral infection, or unfolded proteins, trigger the integrated stress response (ISR), which curtails protein synthesis by phosphorylating eukaryotic translation initiation factor-2α (eIF2α). In T1D, maladaptive unfolded protein response (UPR) in insulin-producing β cells renders these cells susceptible to autoimmunity. We found that inhibition of the eIF2α kinase PKR-like ER kinase (PERK), a common component of the UPR and ISR, reversed the mRNA translation block in stressed human islets and delayed the onset of diabetes, reduced islet inflammation, and preserved β cell mass in T1D-susceptible mice. Single-cell RNA-Seq of islets from PERK-inhibited mice showed reductions in the UPR and PERK signaling pathways and alterations in antigen-processing and presentation pathways in β cells. Spatial proteomics of islets from these mice showed an increase in the immune checkpoint protein programmed death-ligand 1 (PD-L1) in β cells. Golgi membrane protein 1, whose levels increased following PERK inhibition in human islets and EndoC-βH1 human β cells, interacted with and stabilized PD-L1. Collectively, our studies show that PERK activity enhances β cell immunogenicity and that inhibition of PERK may offer a strategy for preventing or delaying the development of T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

eIF-2 KinaseDiabetes Mellitus, Type 1AnimalsMiceHumansInsulin-Secreting CellsMice, Inbred NODUnfolded Protein ResponseEukaryotic Initiation Factor-2

Stichwörter der Autor:innen

Beta cellsDiabetesEndocrinologyPharmacology

Substanzen

eIF-2 KinaseEukaryotic Initiation Factor-2EIF2AK3 protein, human

Autor:innen und Institutionen

  • Department of Medicine and the Kovler Diabetes Center, The University of Chicago, Chicago, Illinois, USA.
  • HiberCell Inc., New York, New York, USA.
  • ULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium.
  • Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.
  • Department of Pathology, The University of Chicago, Chicago, Illinois, USA.
  • Department of Pediatrics, Center for Diabetes and Metabolic Diseases, Wells Center for Pediatric Research, and.

Förderung

  • NIDDK NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • JDRF
  • Diabetes Research Connection
  • Hibercell

Zitieren

APA

Muralidharan, C., Huang, F., Enriquez, J. R., Wang, J. E., Nelson, J. B., Nargis, T., May, S. C., Chakraborty, A., Figatner, K. T., Navitskaya, S., Anderson, C. M., Calvo, V., Surguladze, D., Mulvihill, M. J., Yi, X., Sarkar, S., Oakes, S. A., Webb-Robertson, B. M., Sims, E. K., …, & Mirmira, R. G. (2024). Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci176136

Vancouver

Muralidharan C, Huang F, Enriquez JR, Wang JE, Nelson JB, Nargis T, et al. Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice. Journal of Clinical Investigation. 2024. doi:10.1172/jci176136

BibTeX
@article{Muralidharan2024,
  author = {Muralidharan, Charanya and Huang, Fei and Enriquez, Jacob R and Wang, Jiayi E and Nelson, Jennifer B and Nargis, Titli and May, Sarah C and Chakraborty, Advaita and Figatner, Kayla T and Navitskaya, Svetlana and Anderson, Cara M and Calvo, Veronica and Surguladze, David and Mulvihill, Mark J and Yi, Xiaoyan and Sarkar, Soumyadeep and Oakes, Scott A and Webb-Robertson, Bobbie-Jo M and Sims, Emily K and Staschke, Kirk A and Eizirik, Decio L and Nakayasu, Ernesto S and Stokes, Michael E and Tersey, Sarah A and Mirmira, Raghavendra G},
  title = {Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci176136}
}
Kostenlos starten →